#Canada #Hamilton #Ac-225 #radiopharmaceuticals #IONETIX

AtomVie Global Radiopharma Partners with Ionetix Corporation

In a significant move towards advancing cancer treatment, AtomVie Global Radiopharma, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, has entered into a strategic partnership with Ionetix Corporation. This collaboration is aimed at accelerating the development and availability of Actinium-225 (Ac-225), a pioneering radioisotope pivotal in radiotherapeutics intended for clinical use.

Strengthening Supply Chains

The partnership signifies an important step for AtomVie, which is focused on enhancing its supply chain for Ac-225, an alpha-emitting radioisotope essential for developing targeted radiotherapies. Under this agreement, Ionetix Corporation will supply AtomVie with high-quality Ac-225 that meets current Good Manufacturing Practices (cGMP). This high standard ensures that the isotopes are pure and suitable for use in therapeutic applications, which is a critical requirement for pharmaceutical development.

With the increasing global demand for radiopharmaceuticals, particularly those leveraging alpha therapies, securing a robust supply of Ac-225 is crucial. As AtomVie prepares to launch its state-of-the-art production facility, the timely availability of quality radioisotopes like Ac-225 is set to play a vital role in supporting clinical advancements, from initial research stages through to product commercialization.

CEO's Insights

Bruno Paquin, the Chief Executive Officer of AtomVie, expressed enthusiasm regarding this collaboration, stating, "Access to reliable, high-quality alpha-emitting isotopes like Ac-225 is vital for the next generation of targeted radiopharmaceuticals." The partnership, he notes, will bolster AtomVie’s capabilities to support clients in developing innovative alpha therapies while ensuring the clinical supply chain remains intact as they ready their new facility for operations.

This integration of a dependable isotope supply directly into AtomVie’s development and manufacturing services aims to create added value for their clients and extend their product pipeline focused on Ac-225-based therapeutics.

Broader Implications and Future Directions

David Eve, Vice President of Medical Affairs at Ionetix, addressed the essence of their partnership by reflecting on the rapid evolution of targeted radiopharmaceuticals. He affirmed their joint commitment to facilitating a more consolidated and scalable path towards providing promising alpha therapies for patients. This strategic alliance not only emphasizes innovation in the field of radiopharmaceuticals but also addresses the rising global demand for effectively developed alpha therapies.

About AtomVie Global Radiopharma

AtomVie is a recognized leader in the CDMO domain for GMP-compliant manufacturing and distribution of both clinical and commercial radiopharmaceuticals. Its comprehensive range of services encompasses scientific, technical, regulatory, quality assurance, and logistical abilities tailored to the specific needs of radiopharmaceutical development from clinical trials (Phase I to III) to commercial markets. AtomVie is currently collaborating with clients conducting clinical research across over 28 countries worldwide.

As part of their expansion, AtomVie is set to open a new, modern facility spanning 72,300 square feet, which is slated to commence operations in the first quarter of 2026. This facility will enhance their production capabilities and facilitate the ongoing development of cutting-edge radiopharmaceutical therapies.

About Ionetix Corporation

Ionetix stands out as a leader in cyclotron technology and radioisotope production, providing innovative solutions to enhance access to rare isotopes for both diagnostic and therapeutic applications in radiopharmaceuticals. The company's commitment to ensuring the supply of high-purity isotopes, such as Ac-225 and Astatine-211, for targeted alpha therapies (TATs) underlines its vital role in supporting advancements in this pioneering sector.

In summary, the partnership between AtomVie and Ionetix represents a significant progression in the field of radiopharmaceuticals, promising to meet the growing needs of the healthcare industry while enhancing treatment options for patients worldwide.